Seattle’s startup ecosystem proved once again in 2025 that innovation thrives where technology, science, and vision intersect.
From health data pioneers to aerospace disruptors, companies across industries attracted capital to accelerate their growth. Series C funding rounds represented not only confidence from investors but also a clear sign that these startups are ready to scale globally.
This blog post showcases seven Seattle-area companies that secured Series C funding in 2025. Each one embodies the strength of the Pacific Northwest’s entrepreneurial environment. By looking at who raised capital, how much they secured, and what they plan to achieve next, we can understand the trends shaping the city’s technology future.
Omnidian – $87M
Seattle-based Omnidian closed an $87 million Series C in April 2025. The funding was led by B Capital and supported by existing investors like Activate Capital and Liberty Mutual. This milestone allowed Omnidian to strengthen its role as a trusted solar performance assurance provider.
Omnidian’s mission is straightforward: protect and optimize the growing investments in solar energy. With its monitoring and maintenance services, the company ensures that solar panels and storage systems deliver consistent performance. For customers, this means reliability and peace of mind in an era of expanding clean energy adoption.
With this raise, Omnidian is preparing to expand its footprint nationally. It will use the capital to accelerate hiring, scale its technology infrastructure, and build deeper partnerships with utilities and solar installers. Its growth story reflects how Seattle is becoming a hub for clean energy innovation.
Umoja Biopharma – $100M
In January 2025, Umoja Biopharma secured $100 million in Series C funding, co-led by Double Point Ventures and DCVC Bio. This Seattle biotech specializes in reprogramming a patient’s immune system inside the body to generate cancer-fighting cells.
The funding represents a critical step in advancing clinical trials and expanding manufacturing capabilities. Umoja’s unique platform technology could make therapies more accessible by eliminating the need for complex lab-based cell modifications. Instead, the body itself becomes the engine for treatment.
Beyond cancer, Umoja envisions applications across immunology and chronic diseases. This funding round underscores investor confidence in biotech solutions designed to scale beyond traditional barriers. Seattle’s reputation as a biotech powerhouse continues to grow thanks to companies like Umoja.
Tecton – $100M
Seattle welcomed another major raise when Tecton announced a $100 million Series C in July 2025. Led by Kleiner Perkins and supported by strategic investors such as Snowflake and Databricks, this funding brought Tecton closer to its vision of being the central nervous system for machine learning applications.
Tecton provides a feature platform for machine learning. Its infrastructure helps enterprises manage, automate, and share features that feed AI models. By bridging the gap between raw data and production-ready features, the platform reduces complexity for data science teams.
With AI adoption surging across industries, Tecton’s tools empower businesses to operationalize machine learning at scale. The Series C capital will fuel product development, international expansion, and deeper integration with cloud platforms.
Statsig – $100M
Bellevue-based Statsig, just outside Seattle, raised $100 million in May 2025. Iconiq Growth led the round, alongside Sequoia and Madrona. The raise valued the company at $1.1 billion, granting Statsig unicorn status.
Statsig provides a platform that allows engineering and product teams to run experiments, manage feature rollouts, and analyze user behavior. Its one-stop platform integrates A/B testing, feature flags, analytics, and session replay into a seamless environment.
With this funding, Statsig aims to become indispensable for companies building data-driven products. The capital will support AI-powered capabilities, expand enterprise adoption, and help scale its global reach. Bellevue and Seattle continue to shine as leaders in the future of experimentation platforms.
Temporal – $146M
Temporal, a Seattle-based developer platform, raised $146 million in Series C funding in March 2025. Tiger Global led the round, with participation from Sequoia and other investors. The raise placed Temporal’s valuation around $1.7 billion.
The company offers a workflow orchestration framework that enables developers to build resilient microservices. Temporal’s platform ensures reliability in applications that require complex coordination, from fintech systems to AI-powered workflows.
This funding will allow Temporal to extend its technology into agentic AI development. By blending orchestration with intelligent decision-making, Temporal is positioned at the heart of next-generation applications. Seattle’s developer ecosystem has become even stronger thanks to this milestone.
Stoke Space – $260M
Kent-based Stoke Space, part of the greater Seattle area, secured $260 million in January 2025. The round included support from Breakthrough Energy Ventures and Industrious Ventures, among others.
Stoke is building 100% reusable rockets designed for medium-lift missions. Its Nova rocket incorporates advanced propulsion systems and a reusable upper-stage heat shield. These innovations aim to dramatically cut launch costs and enable higher launch frequency.
The funding will accelerate testing and manufacturing. With reusable rockets at the core of its mission, Stoke Space is making space more accessible while boosting Seattle’s growing aerospace cluster.
Truveta – $320 M
Bellevue’s Truveta made headlines with a massive $320 million Series C in January 2025. Investors included Regeneron Genetics and Illumina, alongside health systems nationwide.
Truveta aggregates de-identified health records and is now building one of the largest genomic databases in the world. By linking genetic data with clinical outcomes, Truveta is driving research into precision medicine and new treatment pathways.
This raise positions Truveta as a leader at the intersection of health data and genomics. The company’s expansion reflects the increasing importance of Seattle as a hub for health innovation. The combination of clinical insights and genomics may redefine medical research globally.
Seattle’s Momentum Continues
Seattle’s 2025 Series C funding rounds highlight the city’s dynamic strengths. Companies across biotech, clean energy, aerospace, developer tools, and data platforms secured significant backing. Each raise demonstrates investor trust in the region’s innovation ecosystem.
The city’s startups are scaling globally while reinforcing the Pacific Northwest’s position as a technology leader. Moreover, Seattle’s ability to attract diverse capital mirrors the benefits of nearshore collaboration, which unites talent, vision, and execution across borders.
Seattle’s ecosystem in 2025 is not only funding ambitious projects but also laying the groundwork for the technologies and industries of tomorrow. From oncology to orbital rockets, the city’s visionaries are writing the next chapter of innovation.
Contact us to learn more about our software development services, and follow us on LinkedIn for more tech trends.
FAQ
Which Seattle company raised the largest Series C round in 2025?
Truveta secured the largest Series C round in Seattle during 2025, raising $320 million to advance its genomic and health data platform. This raise reflected strong confidence in precision medicine and the potential of linking genetic data with clinical outcomes.
How much did Stoke Space raise in its Series C funding?
Stoke Space, based in Kent near Seattle, raised $260 million in January 2025. The funding supports development of its fully reusable Nova rocket, aiming to reduce costs and increase launch frequency in the space industry.
Which sectors dominated Series C funding in Seattle in 2025?
Biotech, health data, and AI-driven developer tools stood out in 2025. Umoja Biopharma and Truveta represented biotech and genomics, while companies like Statsig, Tecton, and Temporal highlighted Seattle’s growing influence in enterprise software and machine learning infrastructure.
Did Seattle startups reach unicorn status through Series C in 2025?
Yes, Statsig reached unicorn status with its $100 million Series C round led by Iconiq Growth, valuing the company at $1.1 billion. Temporal also crossed into billion-dollar valuation territory with its $146 million raise.
How does Series C funding differ from earlier stages?
Series C funding generally signals that a company has proven its model and is ready to scale aggressively. At this stage, startups often expand internationally, strengthen infrastructure, and pursue acquisitions. The focus shifts from validation to large-scale growth.
What does Seattle’s Series C activity say about its tech ecosystem?
Seattle’s Series C activity in 2025 demonstrates the city’s strength across industries. From biotech breakthroughs to clean energy and developer tools, investors are backing companies that align with global innovation priorities. The ecosystem shows resilience, diversity, and a readiness to scale technologies worldwide.
